Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rogaratinib + atezolizumab
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Rogaratinib + atezolizumab** is an investigational combination therapy for locally advanced or metastatic urothelial carcinoma (UC), specifically in cisplatin-ineligible patients whose tumors overexpress FGFR1/3 mRNA. Rogaratinib is an orally administered, selective, pan-fibroblast growth factor receptor (FGFR) inhibitor. Atezolizumab is a monoclonal antibody targeting programmed cell death ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor. This combination is designed to overcome tumor resistance observed in FGFR-overexpressing UC and broaden the population benefiting from immunotherapy. The recommended phase 2 dose is rogaratinib 600 mg twice daily plus intravenous atezolizumab 1200 mg every 21 days. In phase 1b clinical studies (FORT-2), this regimen demonstrated manageable safety and promising efficacy, with objective responses independent of PD-L1 status or FGFR3 genetic alterations.
- Other names
- rogaratinib + atezolizumabFORT-2 regimenFORT2 regimenFORT 2 regimen
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)CSF1R (Macrophage colony-stimulating factor receptor)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)CD274 (Programmed cell death protein 1 ligand 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on rogaratinib + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rogaratinib + atezolizumab.